TITLE

Biogen Idec Excels on Tecidera Launch

AUTHOR(S)
Shaffer, Catherine
PUB. DATE
July 2013
SOURCE
BioWorld Today;7/26/2013, Vol. 24 Issue 142, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the sales of the multiple sclerosis (MS) drug Tecfidera by biopharmaceutical firm Biogen Idec Inc. in the second quarter of 2013. It mentions that the outstanding sales of the drug has contributed 192 million dollars to the total revenues of the company for the quarter. The total revenues of the firm have reached 1.7 billion dollars.
ACCESSION #
89642236

 

Related Articles

  • Biogen Plunges as Forecast Cut, Top Drugs Sales Disappoint.  // MondayMorning;7/27/2015, Vol. 23 Issue 27, p1 

    The article focuses on the growth in sales, revenue, and earnings of Biogen Inc., a biotechnology company, in 2015 while the company's sales for multiple-sclerosis drug Tecfidera has declined. Topics discussed include the expectation of the company to post its per-share earnings, the safety...

  • Biogen Idec and Elan Move Up Antegren Filing.  // Chemical Market Reporter;2/23/2004, Vol. 265 Issue 8, p2 

    Reports that biotechnology firms Biogen Idec and Elan Corp. expect to reduce a year off the anticipated development time for the multiple sclerosis treatment Antegren.

  • ROYALTY PHARMA LLC.  // MondayMorning;4/15/2013, Vol. 21 Issue 14, p1 

    The article offers information on the easing of its 6.6 billion U.S. dollars offer for pharmaceutical company Elan Corp. PLC by the company Royalty Pharma LLC. It mentions that Royalty Pharma LLC will pay more to the shareholders of Elan Corp. PLC if multiple sclerosis drug Tysabri achieves...

  • Biogen Surges as MS Pill Meets Study Goals.  // MondayMorning;10/31/2011, Vol. 19 Issue 39, p1 

    The article discusses a comparative study on the sales of two multiple sclerosis oral drugs namely BG-12 from Biogen Idec Inc. and Copaxone from Teva Pharmaceutical Industries Ltd. It mentions the popularity gained by BG-12 after the second phase of clinical trials and states that the drug...

  • Biogen, Gilead Earnings Crush Q2 Estimates. AMY REEVES // Investors Business Daily;7/24/2014, pA01 

    Big-cap biotech leaders

  • Biogen announces new approach for treatment of multiple sclerosis.  // PharmaWatch: CNS;Aug2011, Vol. 10 Issue 8, p7 

    The article reports on the approach to be implemented by Biogen Idec Inc. for the treatment of patients with multiple sclerosis.

  • Tecfidera captures nearly half of MS market in the USA.  // PharmacoEconomics & Outcomes News;Dec2014, Vol. 717 Issue 1, p40 

    The article reports that the oral disease-modifying therapy (DMT) for multiple sclerosis (MS) from Biogen Idec called Tecfidera has captured nearly 50 percent of the second-line share of newly-diagnosed MS patients, according to a media release from Decision Resources Group.

  • Biogen IDEC Grows on Sales, Rises on BG-12 Data as Well. Breindl, Anette // BioWorld Today;4/22/2011, Vol. 22 Issue 78, p1 

    The article reports on the financial performance of Biogen Idec for the first quarter of 2011. The company posted a 9% increase in revenues during the quarter. It outlines the rate of increase in sales posted by the company's multiple sclerosis drug Tysabri (natalizumab) and its other MS drug...

  • Tecfidera to Treat MS.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, pA-27 

    The article informs that the dimethyl fumarate capsules Tecfidera from Biogen Idec Inc. has been approved for the oral treatment of multiple sclerosis (MS).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics